- Bloom Health (BLMH) has reported Q2 2022 revenue of C$11.1M, up 92.1 per cent from Q1 2022
- EBITDA for the quarter was $2.1M, up from (497,169) in Q2 2021
- FY 2022 YTD revenue stands at $16.9M with full-year guidance estimated to be $25M-$28M
- Bloom Health Partners offers a global platform for health care security, diagnostic testing and occupational health-tech
- Bloom Health (BLMH) is up by 50 per cent trading at $0.18 per share
Bloom Health (BLMH) has reported Q2 2022 revenue of C$11.1M, up 92.1 per cent from Q1 2022.
Q2 2022 financial snapshot
- EBITDA for the quarter was $2.1M, up from (497,169) in Q2 2021
- Cash on hand as of March 31, 2022, was $1.7M with receivables of $8.7M
- FY 2022 YTD revenue stands at $16.9M
Operational highlights
- Secured a COVID-testing contract with K-12 schools in Texas
- Announced the Bloom Shield health-tech platform to manage employee health and risk requirements in the workplace
- Welcomed seasoned health care executive Rosemary Elliston (Cancer Treatment Centers of America, Kaiser Permanente) as its new COO
Bloom anticipates positive EBITDA and revenue between $25M-$28M in FY 2022 as it grows its end-to-end platform of data, laboratories and clinical operations.
“We continue to deliver what we’ve committed to clients and shareholders,” stated Andrew Morton, CEO of Bloom Health. “Our Fiscal Q2 2022 revenue of $11.1M and EBITDA of $2.1M show our team’s ability to grow the business rapidly and scale efficient operations. Bloom is successfully evolving into a premium provider of operational health and health-tech to Fortune 500, film/TV productions and large organizations.”
Bloom Health Partners offers a global platform for health care security, diagnostic testing and occupational health-tech.
Bloom Health (BLMH) is up by 50 per cent trading at $0.18 per share as of 10:51 am EST.